Johnson & Johnson collaborates with Telangana-based Biological E to manufacture COVID-19 vaccine

 

In a statement, Johnson & Johnson said, "We're working around clock to develop & broadly activate manufacturing capabilities to supply vaccine worldwide."

 

Johnson and Johnson further added," We believe Biological E. will be an important part of our global COVID-19 vaccine supply network, where multiple manufacturing sites are involved in the production of our vaccine across different facilities, sometimes in different countries and continents, before the vaccine can be distributed."

 

 

"At Johnson & Johnson, we remain fully focused on bringing a safe and effective Covid-19 vaccine to people around the world, if authorized for use by local health authorities. We are in discussions with the Government of India to start a bridging clinical study of our Janssen Covid-19 vaccine candidate in India, subject to local regulatory approvals," a company statement said.

 

 

 

The company's vaccine named is currently approved for use in the United States, J&J's Janssen COVID-19 vaccine is single - shot COVID vaccine. According to the vaccine manufacturing company, will become efficacious about 28 days after inoculation. The vaccine has an 85.4% efficacy against severe disease and hospitalisation, 66.9% against symptomatic moderate and severe infection.

 

 

It was approved by the FDA under an Emergency Use Authorization for vaccinating those 18 years of age and older in February 2021. Later, the European Union and other nations including Thailand and South Africa also approved the vaccine for emergency use.

.

.